Subcutaneous trastuzumab (Herceptin) versus intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: A time, motion and cost assessment study in a lean operating day care oncology unit
Keywords: صبور; Trastuzumab; Breast; Cancer; Subcutaneous; SC; Intravenous; IV; Lean; Cost; Time; Patient; Capacity;